M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma.
Angiogenesis
EMT
Exosomes
M2 macrophages
Vascular permeability
miR-23a-3p
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
30 10 2023
30 10 2023
Historique:
received:
17
01
2022
accepted:
31
03
2022
medline:
2
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
Metastasis is a key feature of malignant tumors and significantly contributes to their high mortality, particularly in hepatocellular carcinoma (HCC). Therefore, it is imperative to explore the mechanism of tumor metastasis. Recently, tumor-associated macrophages (TAMs) have been demonstrated to promote tumor progression, while TAM-derived molecules involved in HCC metastasis warrant further investigation. THP-1 was treated with IL-4 (Interleukin-4) and IL-13 (Interleukin-13) for M2 polarized macrophages. Exosomes derived from M2 macrophages were characterized. Then, HCC cells or human umbilical vein endothelial cells (HUVECs) were co-cultured with M2 macrophages or treated with M2 macrophage-secreted exosomes. Next, Transwell®, Scratch assay, tube formation, and endothelial permeability assays were performed. Moreover, RT-PCR, western blotting, immunofluorescence, and ELISA were used to assess mRNA and protein expression levels. Finally, the miRNA expression profiles of exosomes derived from M2 and M0 macrophages were analyzed. M2 macrophage infiltration was correlated with metastasis and a poor prognosis in HCC patients. M2-derived exosomes were absorbed by HCC and HUVEC cells and promoted the epithelial-mesenchymal transition (EMT), vascular permeability, and angiogenesis. Notably, MiR-23a-3p levels were significantly higher in M2-derived exosomes and hnRNPA1 mediated miR-23a-3p packaging into exosomes. Phosphatase and tensin homolog (PTEN) and tight junction protein 1 (TJP1) were the targets of miR-23a-3p, as confirmed by luciferase reporter assays. Lastly, HCC cells co-cultured with M2-derived exosomes secreted more GM-CSF, VEGF, G-CSF, MCP-1, and IL-4, which in turn further recruited M2 macrophages. Our findings suggest that M2 macrophage-derived miR-23a-3p enhances HCC metastasis by promoting EMT and angiogenesis, as well as increasing vascular permeability. Video Abstract.
Sections du résumé
BACKGROUND
Metastasis is a key feature of malignant tumors and significantly contributes to their high mortality, particularly in hepatocellular carcinoma (HCC). Therefore, it is imperative to explore the mechanism of tumor metastasis. Recently, tumor-associated macrophages (TAMs) have been demonstrated to promote tumor progression, while TAM-derived molecules involved in HCC metastasis warrant further investigation.
METHODS
THP-1 was treated with IL-4 (Interleukin-4) and IL-13 (Interleukin-13) for M2 polarized macrophages. Exosomes derived from M2 macrophages were characterized. Then, HCC cells or human umbilical vein endothelial cells (HUVECs) were co-cultured with M2 macrophages or treated with M2 macrophage-secreted exosomes. Next, Transwell®, Scratch assay, tube formation, and endothelial permeability assays were performed. Moreover, RT-PCR, western blotting, immunofluorescence, and ELISA were used to assess mRNA and protein expression levels. Finally, the miRNA expression profiles of exosomes derived from M2 and M0 macrophages were analyzed.
RESULTS
M2 macrophage infiltration was correlated with metastasis and a poor prognosis in HCC patients. M2-derived exosomes were absorbed by HCC and HUVEC cells and promoted the epithelial-mesenchymal transition (EMT), vascular permeability, and angiogenesis. Notably, MiR-23a-3p levels were significantly higher in M2-derived exosomes and hnRNPA1 mediated miR-23a-3p packaging into exosomes. Phosphatase and tensin homolog (PTEN) and tight junction protein 1 (TJP1) were the targets of miR-23a-3p, as confirmed by luciferase reporter assays. Lastly, HCC cells co-cultured with M2-derived exosomes secreted more GM-CSF, VEGF, G-CSF, MCP-1, and IL-4, which in turn further recruited M2 macrophages.
CONCLUSIONS
Our findings suggest that M2 macrophage-derived miR-23a-3p enhances HCC metastasis by promoting EMT and angiogenesis, as well as increasing vascular permeability. Video Abstract.
Identifiants
pubmed: 37904170
doi: 10.1186/s12964-022-00872-w
pii: 10.1186/s12964-022-00872-w
pmc: PMC10614338
doi:
Substances chimiques
MicroRNAs
0
Interleukin-4
207137-56-2
Types de publication
Video-Audio Media
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
299Informations de copyright
© 2023. The Author(s).
Références
Mol Cancer. 2019 Aug 13;18(1):124
pubmed: 31409361
Theranostics. 2019 Mar 16;9(7):1965-1979
pubmed: 31037150
Int J Cancer. 2010 May 1;126(9):2102-11
pubmed: 19795442
Cancer Lett. 2006 Jul 18;238(2):180-7
pubmed: 16084013
Curr Opin Genet Dev. 2008 Feb;18(1):27-34
pubmed: 18282701
Hepatol Int. 2008 Jun;2(2):237-43
pubmed: 19669310
Gastroenterology. 2016 Jun;150(7):1646-1658.e17
pubmed: 26924089
Gut. 2017 Jan;66(1):157-167
pubmed: 26452628
Cancer Lett. 2014 Oct 1;352(2):160-8
pubmed: 24892648
Front Oncol. 2019 May 22;9:421
pubmed: 31192126
Sci Transl Med. 2020 Feb 12;12(530):
pubmed: 32051227
J Cell Biol. 1982 Oct;95(1):333-9
pubmed: 7142291
Physiol Rev. 2004 Jul;84(3):869-901
pubmed: 15269339
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncogene. 2017 Aug 24;36(34):4929-4942
pubmed: 28436951
Cancer Res. 2019 Jan 1;79(1):146-158
pubmed: 30401711
Surg Oncol. 2001 Jul-Aug;10(1-2):35-42
pubmed: 11719027
Hepatology. 2018 Oct;68(4):1459-1475
pubmed: 29637568
Mol Cancer. 2019 Mar 11;18(1):39
pubmed: 30857545
Cancer Cell. 2016 Oct 10;30(4):533-547
pubmed: 27728804
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
Nat Commun. 2018 Dec 19;9(1):5395
pubmed: 30568162
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Cancer Res. 2020 Mar 1;80(5):1102-1117
pubmed: 31911557
J Clin Invest. 2019 Dec 2;129(12):5151-5162
pubmed: 31638600
Gut. 2019 Oct;68(10):1846-1857
pubmed: 31154396
Nat Rev Cancer. 2007 Feb;7(2):139-47
pubmed: 17218951
CA Cancer J Clin. 2012 Nov-Dec;62(6):394-9
pubmed: 23070690
Oncogenesis. 2018 May 25;7(5):41
pubmed: 29799520
J Control Release. 2020 May 10;321:23-35
pubmed: 32035193
Surg Today. 2012 Jan;42(1):1-7
pubmed: 22116397
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
Cancer Cell. 2013 Oct 14;24(4):481-98
pubmed: 24035453
Nat Commun. 2017 Nov 6;8(1):1319
pubmed: 29105655